Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Deeplink Medical has centered its offerings around the MIRIO platform, which is designed to cater to the varying use cases and requirements of stakeholders engaged in medical imaging within oncology, both in clinical settings and routine practice. Our services encompass three distinct yet interconnected solutions: MIRIO, which tracks evaluations of solid tumors and monitors the therapeutic responses of oncology patients; a streamlined patient pathway that bridges hospital facilities with private medical practices; and an Imaging CRO dedicated to the oversight of imaging data in oncological clinical trials. The development of our innovative solutions is bolstered by a scientific board, ensuring a robust foundation for our offerings. Additionally, our collaborative workflow platform organizes imaging data and radiological assessments for patients with solid tumors, facilitating real-time data structuration in accordance with RECIST 1.1 and iRECIST guidelines right from the moment the data is generated at investigation sites. This enables immediate evaluation of treatment responses based on established international standards, ultimately enhancing the quality and efficiency of patient care in oncology. By integrating these services, we aim to provide a comprehensive approach that supports healthcare professionals in delivering optimal treatment outcomes.
Description
Omda Cytodose, an oncology medication management solution from Omda, employs clinically validated protocols along with patient-specific parameters to ensure safer and more effective treatments for individuals battling cancer. This innovative system enhances the quality of care provided to oncology patients by fostering a seamless and collaborative treatment process among healthcare professionals, including doctors, pharmacists, and nurses. Omda Cytodose is designed to support a comprehensive range of adult and pediatric cancers, accommodating various medical treatments such as chemotherapy, immunotherapy, hormone therapy, and additional supportive medications. Initially created by a team of clinicians at one of Norway's premier cancer centers and introduced in 2001, Omda Cytodose has gained widespread adoption across healthcare regions in the Nordic countries, leading to the fulfillment of millions of medication orders. With a robust 15-year history marked by stability, reliability, and safety, the system is meticulously configured with chemotherapy protocols that reflect both national and international guidelines. This ensures that patients receive the most up-to-date treatment options available, further enhancing their chances of successful outcomes.
API Access
Has API
API Access
Has API
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
DEEPLINK MEDICAL
Country
France
Website
www.deeplink-medical.com/en/medical-imaging-in-oncology/
Vendor Details
Company Name
Omda
Founded
1999
Country
Norway
Website
omda.com/solutions/medication-management/omda-cytodose/
Product Features
Medical Imaging
Automated Routing
Comparison View
Compliance Management
Data Import / Export
Diagnostic Reporting
Image Analytics
Treatment Planning
Workflow Management